2 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
The primary objective of this study is to determine the equivalence accuracy of energy expenditure and resting heart rate measurement of newly developed software in reference to currently approved software. Secondary objective is to asses the…